OSTA-GAIN
New member
We have in stock
Clinical development (GTx, Inc.)
OstarineTM is an aryl propionamide SARM and the most advanced clinical candidate. OstarineTM demonstrated exciting data in an initial proof-of-concept Phase IIa clinical trial. GTx, Inc. reported in December 2006 the results of this clinical trial, which was a double blind, randomized, placebo-controlled trial in sixty elderly men and sixty postmenopausal women [Dalton, 2007a; Dalton, 2007b]. Without a prescribed diet or exercise regimen, all subjects treated with OstarineTM had a dose-dependent increase in total LBM, with the 3 mg/day cohort achieving an increase of 1.3 kg compared to baseline and 1.4 kg compared to placebo after 3 months of treatment. Treatment with OstarineTM also resulted in a dose-dependent improvement in functional performance measured by a stair climb test, with the 3 mg/day cohort achieving clinically significant improvement in speed and power. Interestingly, subjects treated with 3 mg/d of OstarineTM had on average an 11% decline in fasting blood glucose, a 17% reduction in insulin levels, and a 27% reduction in insulin resistance (homeostasis model assessment) as compared to baseline, suggesting that sarms might have therapeutic potential in diabetics or people at risk for diabetes. Phase I clinical studies with OstarineTM showed that it was rapidly absorbed after oral administration with a half-life of about 1 day (unpublished data).
LOOK AT THESE STUDIES ....WOW
Clinical development (GTx, Inc.)
OstarineTM is an aryl propionamide SARM and the most advanced clinical candidate. OstarineTM demonstrated exciting data in an initial proof-of-concept Phase IIa clinical trial. GTx, Inc. reported in December 2006 the results of this clinical trial, which was a double blind, randomized, placebo-controlled trial in sixty elderly men and sixty postmenopausal women [Dalton, 2007a; Dalton, 2007b]. Without a prescribed diet or exercise regimen, all subjects treated with OstarineTM had a dose-dependent increase in total LBM, with the 3 mg/day cohort achieving an increase of 1.3 kg compared to baseline and 1.4 kg compared to placebo after 3 months of treatment. Treatment with OstarineTM also resulted in a dose-dependent improvement in functional performance measured by a stair climb test, with the 3 mg/day cohort achieving clinically significant improvement in speed and power. Interestingly, subjects treated with 3 mg/d of OstarineTM had on average an 11% decline in fasting blood glucose, a 17% reduction in insulin levels, and a 27% reduction in insulin resistance (homeostasis model assessment) as compared to baseline, suggesting that sarms might have therapeutic potential in diabetics or people at risk for diabetes. Phase I clinical studies with OstarineTM showed that it was rapidly absorbed after oral administration with a half-life of about 1 day (unpublished data).
__________________
Our products are for research only and not for human consumption
contact@osta-gain.com
Osta-Gain
Clinical development (GTx, Inc.)
OstarineTM is an aryl propionamide SARM and the most advanced clinical candidate. OstarineTM demonstrated exciting data in an initial proof-of-concept Phase IIa clinical trial. GTx, Inc. reported in December 2006 the results of this clinical trial, which was a double blind, randomized, placebo-controlled trial in sixty elderly men and sixty postmenopausal women [Dalton, 2007a; Dalton, 2007b]. Without a prescribed diet or exercise regimen, all subjects treated with OstarineTM had a dose-dependent increase in total LBM, with the 3 mg/day cohort achieving an increase of 1.3 kg compared to baseline and 1.4 kg compared to placebo after 3 months of treatment. Treatment with OstarineTM also resulted in a dose-dependent improvement in functional performance measured by a stair climb test, with the 3 mg/day cohort achieving clinically significant improvement in speed and power. Interestingly, subjects treated with 3 mg/d of OstarineTM had on average an 11% decline in fasting blood glucose, a 17% reduction in insulin levels, and a 27% reduction in insulin resistance (homeostasis model assessment) as compared to baseline, suggesting that sarms might have therapeutic potential in diabetics or people at risk for diabetes. Phase I clinical studies with OstarineTM showed that it was rapidly absorbed after oral administration with a half-life of about 1 day (unpublished data).
LOOK AT THESE STUDIES ....WOW
Clinical development (GTx, Inc.)
OstarineTM is an aryl propionamide SARM and the most advanced clinical candidate. OstarineTM demonstrated exciting data in an initial proof-of-concept Phase IIa clinical trial. GTx, Inc. reported in December 2006 the results of this clinical trial, which was a double blind, randomized, placebo-controlled trial in sixty elderly men and sixty postmenopausal women [Dalton, 2007a; Dalton, 2007b]. Without a prescribed diet or exercise regimen, all subjects treated with OstarineTM had a dose-dependent increase in total LBM, with the 3 mg/day cohort achieving an increase of 1.3 kg compared to baseline and 1.4 kg compared to placebo after 3 months of treatment. Treatment with OstarineTM also resulted in a dose-dependent improvement in functional performance measured by a stair climb test, with the 3 mg/day cohort achieving clinically significant improvement in speed and power. Interestingly, subjects treated with 3 mg/d of OstarineTM had on average an 11% decline in fasting blood glucose, a 17% reduction in insulin levels, and a 27% reduction in insulin resistance (homeostasis model assessment) as compared to baseline, suggesting that sarms might have therapeutic potential in diabetics or people at risk for diabetes. Phase I clinical studies with OstarineTM showed that it was rapidly absorbed after oral administration with a half-life of about 1 day (unpublished data).
__________________
Our products are for research only and not for human consumption
contact@osta-gain.com
Osta-Gain
